Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP, Global Chief Med. Off. | February 28, 2017 | March 03, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 28, 2017 · Filed March 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,165 |
Ending reported balance
After 2017-02-28 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2017-02-28 · Grant · Acquired 22,934 · Balance 105,384 F1: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2016 and was subject to the completion of the concurrent three-year individual service period. On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Row 2 · 2017-02-28 · Exercise / conversion · Acquired 4,736 · Balance 110,120 F2: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 3 · 2017-02-28 · Tax withholding · Disposed 11,955 · Balance 98,165 Row 4 · 2017-02-28 · Sale · Disposed 30,000 · Balance 68,165 F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.625 to $24.68, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,736 |
Reported balance
After 2017-02-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-02-28 · Exercise / conversion · Disposed 4,736 · Balance 4,736 F2: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F5: Reflects multiple DSU awards with independent vesting schedules. |
| Performance Share UnitsSEC Table II · derivative / convertible security · Expires 2018-12-31 | Direct | 9,923 |
Reported balance
After 2017-02-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-02-28 · Grant · Acquired 9,923 · Balance 9,923 F6: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F7: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will be prorated and released following retirement. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2016 and was subject to the completion of the concurrent three-year individual service period. On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
F2: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.625 to $24.68, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.
F5: Reflects multiple DSU awards with independent vesting schedules.
F6: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F7: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will be prorated and released following retirement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2017 Filed Mar 3, 2017 00:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 9,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005433 · doc4.xml · derivative · entry 6 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,923 Underlying: Common Stock · 9,923 shares Expires 2018-12-31 F6 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F7 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will be prorated and released following retirement. F7 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will be prorated and released following retirement. F7 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will be prorated and released following retirement. F7 · balance_after: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will be prorated and released following retirement. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005433 · doc4.xml · derivative · entry 5 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,736 Underlying: Common Stock · 4,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F5 · balance_after: Reflects multiple DSU awards with independent vesting schedules. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 30,000 | $24.64 | $739,134.00 |
DisclosureSEC source: 0001225208-17-005433 · doc4.xml · nonDerivative · entry 4 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,165 F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.625 to $24.68, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 11,955 | $24.55 | $293,495.25 |
DisclosureSEC source: 0001225208-17-005433 · doc4.xml · nonDerivative · entry 3 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,165 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005433 · doc4.xml · nonDerivative · entry 2 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 22,934 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005433 · doc4.xml · nonDerivative · entry 1 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,384 F1 · shares: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2016 and was subject to the completion of the concurrent three-year individual service period. On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004922 · doc4.xml · derivative · entry 3 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,472 Underlying: Common Stock · 4,777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F3 · balance_after: Reflects multiple DSU awards with independent vesting schedules. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,546 | $24.81 | $38,356.26 |
DisclosureSEC source: 0001225208-17-004922 · doc4.xml · nonDerivative · entry 2 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,450 Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004922 · doc4.xml · nonDerivative · entry 1 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004737 · doc4.xml · derivative · entry 3 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,588 Underlying: Common Stock · 2,293 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 867 | $24.78 | $21,484.26 |
DisclosureSEC source: 0001225208-17-004737 · doc4.xml · nonDerivative · entry 2 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,219 Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004737 · doc4.xml · nonDerivative · entry 1 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004551 · doc4.xml · derivative · entry 3 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,518 Underlying: Common Stock · 1,839 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 831 | $24.48 | $20,342.88 |
DisclosureSEC source: 0001225208-17-004551 · doc4.xml · nonDerivative · entry 2 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,793 Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004551 · doc4.xml · nonDerivative · entry 1 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 22:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004393 · doc4.xml · derivative · entry 3 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,952 Underlying: Common Stock · 1,738 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 22:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 817 | $25.16 | $20,555.72 |
DisclosureSEC source: 0001225208-17-004393 · doc4.xml · nonDerivative · entry 2 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,785 Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 22:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004393 · doc4.xml · nonDerivative · entry 1 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 07, 2017 Filed Feb 8, 2017 21:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 80,783 | $25.21 | $2,036,523.27 |
DisclosureSEC source: 0001225208-17-002653 · doc4.xml · nonDerivative · entry 1 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,864 F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.165 to $25.25, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 11,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-000358 · doc4.xml · derivative · entry 3 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,673 shares Expires 2016-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. F1 · derivative.exercise_date: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. F1 · derivative.expiration_date: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 5,253 | $21.63 | $113,622.39 |
DisclosureSEC source: 0001225208-17-000358 · doc4.xml · nonDerivative · entry 2 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,647 Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 11,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-000358 · doc4.xml · nonDerivative · entry 1 Dawkins Keith D · CIK 0001492253 · EVP, Global Chief Med. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.